Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory for Digestive Health, National Clinical Research Center for Digestive Disease, Beijing ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Results Exploration of the heterogeneity of tumour-associated neutrophils (TANs) revealed a terminally differentiated pro-tumour subpopulation (TAN-1) associated with poor prognosis ... (IF) and ...

Additionally, VENTANA FOLR1 (FOLR1-2.1) RxDx Assay – Roche’s immunohistochemistry (IHC ... (i.e. greater than or equal to 75% tumour cells staining with 2+ intensity). Testing is now available ...

The drug-coating approach has its intrinsic advantages of easy production at low cost without compromising the mechanical property of the suture matrix, whereas the major drawback lies in low drug ...

Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease with a poor prognosis ... mechanism of this is currently unknown. Methods Immunohistochemistry (IHC) staining ...

However, evidence of keratinocyte–immune cell crosstalk in the rosacea lesion and what initially triggers this crosstalk remain poor unknown ... with different rosacea subtypes. Immunohistochemistry ...

CNN reporters and hosts said Monday that President Biden's decision to pardon his family members in the waning minutes of his administration tarnished his reputation and was "a stain on his legacy." ...